Department of Internal Medicine, University of Pittsburgh Medical Center, USA.
Division of Hematology/Oncology, Magee-Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
Breast Cancer (Dove Med Press). 2012 May 23;4:75-81. doi: 10.2147/BCTT.S16356.
Preclinical studies and adjuvant trials using bisphosphonates have found them to have an antitumor effect. Although major advances have been made in chemoprevention strategies with selective estrogen receptor modulators and aromatase inhibitors, their use has been fraught with significant adverse effects such as venous thromboembolic events and an increased risk for endometrial cancer. In this context, several recent observational studies have investigated a chemoprevention role for oral bisphosphonates in decreasing risk for breast cancer. This review will aim to summarize these studies and present a critical evaluation of the association between oral bisphosphonate use and breast cancer risk reduction.
临床前研究和使用双膦酸盐的辅助试验发现它们具有抗肿瘤作用。尽管选择性雌激素受体调节剂和芳香酶抑制剂的化学预防策略取得了重大进展，但它们的使用存在静脉血栓栓塞事件和子宫内膜癌风险增加等重大不良反应。在这种情况下，最近的几项观察性研究调查了口服双膦酸盐在降低乳腺癌风险方面的化学预防作用。本综述旨在总结这些研究，并对口服双膦酸盐使用与乳腺癌风险降低之间的关联进行批判性评估。
